08:00 , Jan 11, 2016 |  BC Week In Review  |  Company News

Cosmo, Ferring deal

Cosmo granted Ferring exclusive rights to develop and commercialize Cortiment MMX in Japan. Ferring already has ex-U.S. and -Japanese rights to Cortiment from Cosmo and will be responsible for conducting clinical trials required for a...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Ferring, NovaMedica deal

Ferring granted NovaMedica exclusive rights to commercialize its line of prescription drug products to treat inflammatory bowel diseases in Russia. NovaMedica said the products include Prepopik sodium picosulfate/magnesium oxide/citric acid, a laxative for cleansing the...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

Ferring sales and marketing update

Ferring launched Cortiment MMX budesonide in Europe to treat adults with active mild to moderate ulcerative colitis in cases where mesalazine has not been sufficient. The approved dose is a 9 mg tablet taken once...
03:27 , Nov 7, 2014 |  BC Extra  |  Top Story

Salix hit on accounting turmoil

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) plunged $53.05 (38%) to $85.50 in after-hours trading on Thursday on news its CFO had resigned and the company had retained outside counsel to investigate how it was accounting for inventory...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Clinical News

Cortiment MMX budesonide regulatory update

Cosmo and Ferring said Cortiment MMX budesonide received approval in 27 EU countries under the Mutual Recognition Procedure to treat mild to moderate active ulcerative colitis (UC). Ferring launched the product in the Netherlands in...
07:00 , Oct 13, 2014 |  BC Week In Review  |  Clinical News

Uceris budesonide rectal foam regulatory update

FDA granted final approval to Uceris budesonide rectal foam from Salix for the induction of remission in patients with active, mild to moderate distal ulcerative colitis (UC) extending up to 40 cm from the anal...
02:20 , Oct 9, 2014 |  BC Extra  |  Company News

FDA approves Uceris rectal foam

FDA approved an NDA for Uceris budesonide rectal foam from Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) to induce remission of mild to moderate distal ulcerative colitis (UC) extending up to 40 cm from the anal verge. Salix...
07:00 , Oct 6, 2014 |  BC Week In Review  |  Clinical News

Uceris budesonide rectal foam regulatory update

FDA granted tentative approval to an NDA for Uceris budesonide rectal foam from Salix for the induction of remission of mild to moderate distal ulcerative colitis (UC) extending up to 40 cm from the anal...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Company News

Salix Pharmaceuticals Ltd, Cosmo deal

Salix will merge with an Irish subsidiary of partner Cosmo in a stock deal that will give Cosmo about a 20% stake in Salix. Salix will become a subsidiary of the Irish subsidiary, Cosmo Technologies...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) was down $0.96 to $10.54 last week after partner Gruenenthal Group submitted an MAA to EMA for Zalviso to treat moderate to severe acute pain. The submission triggered a...